These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26897037)

  • 21. [Chronic kidney disease what is it?].
    Joly D
    Rev Prat; 2012 Jan; 62(1):34-7. PubMed ID: 22335064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal biomarkers for the prediction of cardiovascular disease.
    Joshi S; Viljoen A
    Curr Opin Cardiol; 2015 Jul; 30(4):454-60. PubMed ID: 26049396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rule-Mining for the Early Prediction of Chronic Kidney Disease Based on Metabolomics and Multi-Source Data.
    Luck M; Bertho G; Bateson M; Karras A; Yartseva A; Thervet E; Damon C; Pallet N
    PLoS One; 2016; 11(11):e0166905. PubMed ID: 27861591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers in native and transplant kidneys: opportunities to improve prediction of outcomes in chronic kidney disease.
    De Serres SA; Varghese JC; Levin A
    Curr Opin Nephrol Hypertens; 2012 Nov; 21(6):619-27. PubMed ID: 22914685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urinary neutrophil gelatinase-associated lipocalin may aid prediction of renal decline in patients with non-proteinuric Stages 3 and 4 chronic kidney disease (CKD).
    Smith ER; Lee D; Cai MM; Tomlinson LA; Ford ML; McMahon LP; Holt SG
    Nephrol Dial Transplant; 2013 Jun; 28(6):1569-79. PubMed ID: 23328709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal function trajectory over time and adverse clinical outcomes.
    Sohel BM; Rumana N; Ohsawa M; Turin TC; Kelly MA; Al Mamun M
    Clin Exp Nephrol; 2016 Jun; 20(3):379-93. PubMed ID: 26728745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteomic and metabolomic approaches in the search for biomarkers in chronic kidney disease.
    Cañadas-Garre M; Anderson K; McGoldrick J; Maxwell AP; McKnight AJ
    J Proteomics; 2019 Feb; 193():93-122. PubMed ID: 30292816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolomics for clinical use and research in chronic kidney disease.
    Hocher B; Adamski J
    Nat Rev Nephrol; 2017 May; 13(5):269-284. PubMed ID: 28262773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipidomics: new insight into kidney disease.
    Zhao YY; Vaziri ND; Lin RC
    Adv Clin Chem; 2015; 68():153-75. PubMed ID: 25858872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5.
    Alderson HV; Ritchie JP; Middleton R; Larsson A; Larsson TE; Kalra PA
    Nephrology (Carlton); 2016 Jul; 21(7):566-73. PubMed ID: 27334353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic biomarkers for chronic kidney disease.
    Ju W; Smith S; Kretzler M
    Transl Res; 2012 Apr; 159(4):290-302. PubMed ID: 22424432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of ergone by UPLC-QTOF/HDMS.
    Zhao YY; Chen H; Tian T; Chen DQ; Bai X; Wei F
    PLoS One; 2014; 9(12):e115467. PubMed ID: 25535749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early markers of cardiovascular risk in chronic kidney disease.
    Lai S; Dimko M; Galani A; Coppola B; Innico G; Frassetti N; Mazzei ED; Mariotti A
    Ren Fail; 2015 Mar; 37(2):254-61. PubMed ID: 25394527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-acteyl-ß-D-glucosaminidase and kidney injury molecule-1: New predictors for long-term progression of chronic kidney disease in patients with heart failure.
    Jungbauer CG; Uecer E; Stadler S; Birner C; Buchner S; Maier LS; Luchner A
    Nephrology (Carlton); 2016 Jun; 21(6):490-8. PubMed ID: 26422793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble tumor necrosis factor receptor 1 and 2 predict outcomes in advanced chronic kidney disease: a prospective cohort study.
    Neirynck N; Glorieux G; Schepers E; Verbeke F; Vanholder R
    PLoS One; 2015; 10(3):e0122073. PubMed ID: 25823004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary metabonomic study of the surface layer of Poria cocos as an effective treatment for chronic renal injury in rats.
    Zhao YY; Li HT; Feng YL; Bai X; Lin RC
    J Ethnopharmacol; 2013 Jul; 148(2):403-10. PubMed ID: 23612421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting acute kidney injury prognosis.
    Szerlip HM; Chawla LS
    Curr Opin Nephrol Hypertens; 2016 May; 25(3):226-31. PubMed ID: 27023837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current drug development challenges in chronic kidney disease (CKD)--identification of individualized determinants of renal progression and premature cardiovascular disease (CVD).
    Formentini I; Bobadilla M; Haefliger C; Hartmann G; Loghman-Adham M; Mizrahi J; Pomposiello S; Prunotto M; Meier M
    Nephrol Dial Transplant; 2012 Oct; 27 Suppl 3():iii81-8. PubMed ID: 22734108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recognizing the link between CKD and CVD in the primary care setting: accurate and early diagnosis for timely and appropriate intervention.
    Basile JN
    South Med J; 2007 May; 100(5):499-505. PubMed ID: 17534087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Potential Biomarkers for Chronic Kidney Disease Management-A Review of the Literature.
    Lousa I; Reis F; Beirão I; Alves R; Belo L; Santos-Silva A
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.